Corporate Overview Statutory Reports Financial Statements 147 (` cr) Note 21 Revenue from operations 2023-24 2022-23 Sale of products 4,228.26 4,809.76 Sale of services1 73.12 191.78 Scrap sales 14.17 13.62 Revenue from contracts with customers 4,315.55 5,015.16 Export incentives 42.15 46.62 4,357.70 5,061.78 1Includes ` 61.01 cr (2022-23: ` 183.37 cr) on account of freight and insurance in sale of goods on CIF, which are identified as separate performance obligation under Ind AS 115. Disaggregation of revenue from contracts with customers: (` cr) Particulars 2023-24 2022-23 Sale of goods | services Life Science Chemicals 1,257.29 1,476.67 Domestic 701.82 631.82 Export 555.47 844.85 Performance and Other Chemicals 3,272.86 3,822.04 Domestic 1,965.04 2,170.00 Export 1,307.82 1,652.04 Others 2.46 3.89 4,532.61 5,302.60 Inter-segment revenue 217.06 287.44 4,315.55 5,015.16 Reconciliation of revenue from contracts with customers recognised at contract price: (` cr) Particulars 2023-24 2022-23 Contract price 4,415.13 5,089.53 Adjustments for: Consideration payable to customers - discounts1 (93.71) (83.20) Contract price allocated to unsatisfied performance obligation for sale of services (net)2 (5.87) 8.83 Revenue from contracts with customers 4,315.55 5,015.16 1Consideration payable to customers like discounts and price reductions offered to customers are estimated on specific identified basis and reduced from the contract price when the Company recognises revenue from the transfer of the related goods or services to the customer and the entity pays or promises to pay the consideration. 2Unsatisfied performance obligation for sale of services comprises revenue from insurance and freight services for exports in-progress as at March 31, 2024, of ` 13.41 cr, net of revenue recognised for such services for similar contracts in-progress as at March 31, 2023, for ` 7.54 cr. The revenue for exports in-progress as at March 31, 2024, will be recognised in 2024-25 upon completion of the exports.
RkJQdWJsaXNoZXIy MjA2MDI2